for XX% Brett, third for year-to-date. solid quarter you, pleased with and the announce I growth afternoon, XX% quarter am everyone. good growth to the and Thank growth a
annual year full solid to sales million two our compared OsteoVive Fixation to new which approximately growth achieve supplier quarter, today. $XXX on million, and experienced reaffirmed Posterior are revenue growth products,
Despite softer our we to year issues. to total $XXX validation XX% guidance We XXXX. year-over-year expected with pace Plus, delays of stem launch revenue the represents of of full range were the Cortera, XX% due than our in new cell slight met our to System for product, we delays was This new
and well these since were by our product challenges, distributors We in received both have surgeons. lines and released September and are overcome late
products We for help perspective, discussed. $XXX,XXX.
From just believe are on our adjusted remain profitability will Scott moment, effect XXXX. an will I these cover EBITDA basis the reflect EBITDA in product a bullish these delays which of and for we profitable they us fiscal results strong on adjusted QX, Year-to-date, a finish year with
anticipate continue we adjusted addition, as QX on positive EBITDA in XXXX being and self-sustainability. to In focus profitability of we
X continue expenses were become expenses more the lower quarter we immediate the operating as preceding compared rationalize to Our efficient. to third and quarters in
the revenues, fall that no to royalty carry This to little will $X.X we and membrane. October, Simply Max corresponding agreement revenue a with will deal for the in in $X.XX in of care licensing development amniotic licensing of wound high terms this incremental received Another the codes signed in upfront The XQ agreement significant includes important provide costs full and million aggregating We dual-layer our of player a this and payment bottom XXXX. a advanced a line. directly market. minimum our margins for million will, October, licensing and incremental therefore, bear
end million where to we of is context grow. fiscal between us As has only size at in a and of comes the where our business but when of million. $XXX agreements. have to And we $XX will than ago, so the been in XXXX going. year not without business historical business this greatly $XXX business. greater important were assisted million and a made our put Scale revenue to -- XXXX, into a X The taking doubled last have By year we the end GPO it backdrop, our no continued first, acquisitions and less to and scale. Remember, extremely expect this back, we years step are with revenues getting IDN our is growth access hospitals, year,
the hardware line. Surgalign revitalized acquisition Xtant our Secondarily, has
a offering complement second offering includes complete which device cervical posterior Axle, Coflex perfectly fusion offering. instance, that full device none SI Silex complements For devices. device. is stabilization our system, Streamline our our process server ASC-focused interspinous our includes one-of-its-kind alternative a is preservation with XXX-degree motion ASC interlaminar anterior That our a products, and of interbody line to line our Xtant's of system and
our in-house. we screw complete perspective, a rationale for year offering. Cortera, bring of fiscal strategic manufacturing to #X The was best-in-class for pedicle a have With biologics now that was to system all hardware priority
From our the XXXX release twofold.
million the the on lost manufacturing of our by our the our control we end some $XX of wrong disruptions supply fastest-growing with to products. production products we million X this In availability chain, in for supply approximately past and of accounted in-house, been we've believe to products years, revenue our $XX the First, sell.
product we we our margins margins Amnio margins. make importantly, is and products. in profitably supplier companies now substantially these low to Xtant as for profitable an selling stem OEM our making more products growth market the factor, spine markets. other strategically, Xtant synthetic cell for are Moreover, The increased gross positioned and range mid-XXs to XX% mid-XX% to and and Secondly, product margins. products gross more grow the branded adjacent the When substantially from more distributed from in-house, our XX% when
for us our new this Xtant great is with customers spine product and we spine our for line, $X For can instance, our a barrier new margins. brand With we which year Amnio addition serve about to more procedures. substantially surgical a better offering, better sell of expect now a million as
care, any created that XX% ankle expenses, has are in have buying and in customers exceed just
Similarly, part foot ankle only and opportunity about from the markets million stem sales. thereby do and also wound a The terrific OEM carrying not sports medicine OEM in spine, now are over XX% OEM and will not foot Amnio beautiful marketing this year we contribution new $X our Additionally, but this OEM cell the deals Xtant, in now and who trauma line margins. carry and to product sales they markets.
of to integration concern is you keenly our to we to that voiced our to have important businesses Surgalign and find on and leverage. reduce the the our I I would that shifting profitability. operational to leverage. shareholders of One focus assure like like we operational over would Now address complete ways continue now expense directly base all as
previously last increased year decreased As X for fiscal preceding have over to opportunities operating immediately and scale. for mentioned, XXXX. continue leverage to the we look quarterly
Rounding cut the quarters, quarter, our substantially our out and expenses costs
we have chain expected and implemented up So of raised remember, better guidance, fiscal is in the stem challenges revenue distributed Surgalign than our deliver $XXX May, non-manufactured on supply challenges affecting line as the issues our million when it impacted our shaping actions many clear hardware half and guidance gain that over the to to resolved. you products. second work worked with been became we address through was performing in cells year that largely May revenues. half to finally if of with our fourth we We as production control million fastest-growing greater we remain paying off of of the improvements first the established and have We've track breakout most revenue original products. increased what our million a And will hard of $XXX that $XXX million the with believe XXXX to be all our we with quarter back $XXX
moving pipeline. products. pipeline we product deep innovate of a organization, Now healthy, our to robust with Like continually new every new
profile. X demineralized matrix, enhance which factor. expanded we our line synthetics, cells, growth product few or call them, stem and complete which are During bone the our viable offers from turnaround, we to helped we companies offering growth matrix one categories the that of includes our as allograft, product orthobiologics bone biologics of Moreover, X, orthobiologics,
integrated, known completed the quarters, we X we under also the them our mentioned as stem next make own vertically bone be sell own I that and production line years. Over fastest-growing been this Amnio Xtant over better with product where matrix, our will -- products brand. is our the our Along cells, last has orthobiologics company products, have own we that X for only our viable the of
product a upon be relied to grow been growth our due brand the superior a has of significantly However, we stem provider profile, Plus OEM far orthopedic of chain. vendors available be line. believe market we product for believe with continues able the we a other With Xtant there improved significantly. bone to major fiscal constrained outside viable will shortage our will in we product stem cell to with cost In that our largest supply can cells, this profitably XXXX, matrix a and OsteoVive now with we product supply year line. become
Moreover, we companies expect be this our
designs posterior and system. This has comparatively a with NAS, system rave of Pedicle low We a and briefly designed from prospective the screw screw earlier I received is surgeons. Lastly, newly release mentioned locking we our at feature-rich Cortera Cortera next-generation released system mechanisms. reviews that profile a new
for just are short- the
In of will a midterm the drive significant for few Xtant that lifts are future take expect rollout proven beyond. products pipe. We a in short, QX clearances. infrastructure. products opportunities evidence Most regulatory operational require product growth this markets. of winnable will growing These of or help big have fantastic clinically pipeline exciting validated, and commercially and development nice coming These importantly, clinical existing product down products or new not to our overly will in large we they in advantage serve new quality investments and that
patient these less during treatment believe supply our large should production on population. products quarter growing to get to profile, a with on
Moreover, our dramatically self-reliance this are fourth a we and us an will be to product control. of transformative margin forward, own controlling chain self-sustaining by allow EBITDA help larger Most of improve reliant we producing XXXX. our Moving that outside We diverse positive line focused biologics. adjusted and becoming actions importantly, us producer coupled believe to brings the operationally will our additional more options expanded and
to third results. Scott, who our like I'd turn the quarter over will discuss XXXX financial Now call to
